

Raymond W Lam

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1025365/raymond-w-lam-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

382
papers

14,701
citations

63
h-index

106
g-index

412
ext. papers

17,487
ext. citations

5.4
avg, IF

6.44
L-index

#	Paper	IF	Citations
382	Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report.. <i>Cerebellum</i> , 2022 , 1	4.3	
381	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 816465	5	
380	"One Degree of Separation": A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19.. <i>Canadian Journal of Psychiatry</i> , 2022 , 7067437211070656	4.8	0
379	Functional outcomes with bright light in monotherapy and combined with fluoxetine in patients with major depressive disorder: Results from the LIFE-D trial. <i>Journal of Affective Disorders</i> , 2022 , 297, 396-400	6.6	
378	Early Optimized Pharmacological Treatment in Patients With Depression and Chronic Pain.. <i>CNS Spectrums</i> , 2022 , 1-40	1.8	
377	Advancing Implementation Science Measurement for Global Mental Health Research.. <i>Canadian Journal of Psychiatry</i> , 2022 , 7067437221078411	4.8	0
376	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.. <i>Brain and Behavior</i> , 2022 , e2555	3.4	1
375	Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.. <i>Psychiatry Research</i> , 2022 , 312, 114557	9.9	
374	Blue-Light Therapy for Seasonal and Non-Seasonal Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. <i>Canadian Journal of Psychiatry</i> , 2022 , 7067437221097903	4.8	1
373	Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report.. <i>Journal of Psychopharmacology</i> , 2022 , 36, 604-613	4.6	0
372	Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. <i>Journal of Affective Disorders Reports</i> , 2022 , 9, 100370	1.4	
371	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. <i>NeuroImage: Clinical</i> , 2021 , 32, 102864	5.3	1
370	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis.. <i>Psychological Medicine</i> , 2021 , 51, 2742-2751	6.9	3
369	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. <i>Bipolar Disorders</i> , 2021 ,	3.8	6
368	Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble Dépressif Majoritaire. <i>Frontiers in Psychiatry</i> , 2021 , 12, 725252	4.8	
367	Mental Health Service Challenges during the Early Stage of the COVID-19 Pandemic: Experience and Best Practices from China. <i>Canadian Journal of Psychiatry</i> , 2021 , 66, 621-623	4.8	2
366	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 111, 110194	5.5	4

365	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>CNS Drugs</i> , 2021 , 35, 291-304	6.7	0
364	Weight gain as a risk factor for progressive neurochemical abnormalities in first episode mania patients: a longitudinal magnetic resonance spectroscopy study. <i>Psychological Medicine</i> , 2021 , 1-9	6.9	0
363	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. <i>Pharmacopsychiatry</i> , 2021 , 54, 225-231	2	1
362	Efficacy of Active vs Sham Intermittent Theta Burst Transcranial Magnetic Stimulation for Patients With Bipolar Depression: A Randomized Clinical Trial. <i>JAMA Network Open</i> , 2021 , 4, e210963	10.4	9
361	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. <i>CNS Drugs</i> , 2021 , 35, 439-450	6.7	1
360	Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report. <i>Personality and Mental Health</i> , 2021 , 15, 273-282	3.1	
359	White matter microstructure in youth at risk for serious mental illness: A comparative analysis. <i>Psychiatry Research - Neuroimaging</i> , 2021 , 312, 111289	2.9	0
358	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. <i>PLoS ONE</i> , 2021 , 16, e0253023	3.7	1
357	Quality of Life Impacts of Bright Light Treatment, Fluoxetine, and the Combination in Patients with Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial. <i>Canadian Journal of Psychiatry</i> , 2021 , 66, 289-297	4.8	2
356	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommendations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder	4.8	15
355	The Quality of Life in Bipolar Disorder (QoL.BD) questionnaire a decade on - A systematic review of the measurement of condition-specific aspects of quality of life in bipolar-disorder. <i>Journal of Affective Disorders</i> , 2021 , 278, 33-45	6.6	1
354	Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?. <i>Canadian Journal of Psychiatry</i> , 2021 , 66, 185-194	4.8	3
353	Probing the clinical and brain structural boundaries of bipolar and major depressive disorder. <i>Translational Psychiatry</i> , 2021 , 11, 48	8.6	1
352	Implementing Measurement-Based Care for Depression: Practical Solutions for Psychiatrists and Primary Care Physicians. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 79-90	3.1	4
351	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. <i>Translational Psychiatry</i> , 2021 , 11, 127	8.6	5
350	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. <i>Frontiers in Psychiatry</i> , 2021 , 12, 617997	5	3
349	Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report. <i>Communications Biology</i> , 2021 , 4, 903	6.7	2
348	Needs, gaps and opportunities for standard and e-mental health care among at-risk populations in the Asia Pacific in the context of COVID-19: a rapid scoping review. <i>International Journal for Equity in Health</i> , 2021 , 20, 161	4.6	1

347	Exploring brain connectivity changes in major depressive disorder using functional-structural data fusion: A CAN-BIND-1 study. <i>Human Brain Mapping</i> , 2021 , 42, 4940-4957	5.9	3
346	Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials. <i>Journal of Psychiatric Research</i> , 2021 , 140, 267-281	5.2	2
345	Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine : Utiliser l'apprentissage machine pour prédire la rémission chez les patients souffrant de trouble dépressif majeur traité par desvenlafaxine. <i>Canadian Journal of Psychiatry</i> , 2021 , 7067437211037141	4.8	
344	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. <i>Translational Psychiatry</i> , 2021 , 11, 439	8.6	1
343	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report. <i>Cerebral Cortex</i> , 2021 ,	5.1	1
342	The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Psychiatry</i> , 2021 , 82,	4.6	3
341	Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. <i>Translational Psychiatry</i> , 2021 , 11, 469	8.6	
340	Barriers and facilitators to implementing measurement-based care for depression in Shanghai, China: a situational analysis. <i>BMC Psychiatry</i> , 2021 , 21, 430	4.2	1
339	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. <i>Psychoneuroendocrinology</i> , 2021 , 132, 105348	5	0
338	A randomized sham controlled comparison of once vs twice-daily intermittent theta burst stimulation in depression: A Canadian rTMS treatment and biomarker network in depression (CARTBIND) study. <i>Brain Stimulation</i> , 2021 , 14, 1447-1455	5.1	2
337	Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report. <i>Journal of Affective Disorders</i> , 2021 , 295, 1095-1101	6.6	0
336	Exploring the Effects of Temperament on Gray Matter Volume of Frontal Cortex in Patients with Mood Disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 183-193	3.1	1
335	Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach. <i>Frontiers in Neuroinformatics</i> , 2021 , 15, 622951	3.9	1
334	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>Neuropsychopharmacology</i> , 2020 , 45, 1390-1397	8.7	15
333	A Randomized Sham-controlled Trial of 1-Hz and 10-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) of the Right Dorsolateral Prefrontal Cortex in Civilian Post-traumatic Stress Disorder: Un essai randomisé contrôlé de stimulation magnétique transcrânienne répétitive (SMTr) de 1 Hz et 10 Hz du cortex préfrontal dorsolatéral droit dans le trouble de stress	4.8	5
332	Predictors of cognitive impairment in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020 , 274, 593-601	6.6	6
331	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. <i>NeuroImage: Clinical</i> , 2020 , 25, 102178	5.3	4
330	Serum epidermal growth factor, clinical illness course, and limbic brain volumes in early-stage bipolar disorder. <i>Journal of Affective Disorders</i> , 2020 , 270, 30-35	6.6	1

329	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. <i>Innovations in Clinical Neuroscience</i> , 2020 , 17, 30-40	1	3
328	The APEC Digital Hub-WONCA Collaborative Framework on Integration of Mental Health into Primary Care in the Asia Pacific. <i>Journal of Multidisciplinary Healthcare</i> , 2020 , 13, 1693-1704	2.8	1
327	Development and implementation of guidelines for the management of depression: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020 , 98, 683-697H	8.2	15
326	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	5
325	Dr Uher and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2020 , 82,	4.6	1
324	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. <i>Neuropsychopharmacology</i> , 2020 , 45, 283-297	8.7	18
323	Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post- hoc analysis of a randomized double-blind placebo-controlled trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020 , 54, 298-307	2.6	5
322	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. <i>JAMA Network Open</i> , 2020 , 3, e1918377	10.4	20
321	Light Therapy for Patients With Bipolar Depression: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Canadian Journal of Psychiatry</i> , 2020 , 65, 290-300	4.8	15
320	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 68-85	5.8	5
319	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. <i>Journal of Affective Disorders</i> , 2020 , 264, 414-424	6.6	3
318	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. <i>Journal of Affective Disorders</i> , 2020 , 263, 353-366	6.6	4
317	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. <i>Human Brain Mapping</i> , 2020 , 41, 1400-1415	5.9	5
316	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. <i>Journal of Affective Disorders</i> , 2020 , 276, 576-584	6.6	44
315	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2020 , 50, 2536-2547	6.9	6
314	White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019 , 4, 913-924	3.4	11
313	It's more than just a referral: Development of an evidence-informed exercise and depression toolkit. <i>Mental Health and Physical Activity</i> , 2019 , 17, 100297	5	8
312	Structural network integrity of the central executive network is associated with the therapeutic effect of rTMS in treatment resistant depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 92, 217-225	5.5	17

311	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. <i>NeuroImage</i> , 2019 , 197, 589-597	7.9	19
310	Functional disconnectivity of the hippocampal network and neural correlates of memory impairment in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2019 , 253, 248-256	6.6	22
309	Men's Work-Related Stress and Mental Health: Illustrating the Workings of Masculine Role Norms. <i>American Journal of Men's Health</i> , 2019 , 13, 1557988319838416	2.2	6
308	Trajectories of Response to Dorsolateral Prefrontal rTMS in Major Depression: A THREE-D Study. <i>American Journal of Psychiatry</i> , 2019 , 176, 367-375	11.9	50
307	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. <i>Journal of Affective Disorders</i> , 2019 , 257, 765-773	6.6	13
306	The chronotherapeutic treatment of bipolar disorders: A systematic review and practice recommendations from the ISBD task force on chronotherapy and chronobiology. <i>Bipolar Disorders</i> , 2019 , 21, 741-773	3.8	75
305	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. <i>Translational Psychiatry</i> , 2019 , 9, 254	8.6	18
304	Machine learning and big data analytics in bipolar disorder: A position paper from the International Society for Bipolar Disorders Big Data Task Force. <i>Bipolar Disorders</i> , 2019 , 21, 582-594	3.8	52
303	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. <i>Journal of Psychiatry and Neuroscience</i> , 2019 , 44, 223-236	4.5	22
302	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	38
301	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	10
300	Cognitive Dysfunction in the Workplace: Focus on Depression. <i>Integrating Psychiatry and Primary Care</i> , 2019 , 99-110	0.3	1
299	Neurobiological Aspects of Functional Recovery in Major Depressive Disorder 2019 , 277-284		
298	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2019 , 49, 1629-1638	6.9	14
297	Relationship between work functioning and self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine. <i>Psychiatry Research</i> , 2019 , 272, 144-148	9.9	3
296	Weight gain as a predictor of frontal and temporal lobe volume loss in bipolar disorder: A prospective MRI study. <i>Bipolar Disorders</i> , 2019 , 21, 50-60	3.8	14
295	Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. <i>Journal of Affective Disorders</i> , 2019 , 246, 861-866	6.6	5
294	Discrepancy between objective and subjective cognition in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2019 , 29, 46-56	1.2	37

293	Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. <i>Lancet, The</i> , 2018 , 391, 1683-1692 ⁴⁰		365
292	Implications of Cannabis Legalization on Youth and Young Adults. <i>Canadian Journal of Psychiatry</i> , 2018 , 63, 65-71	4.8	14
291	Abnormal Functional Connectivity of Frontopolar Subregions in Treatment-Nonresponsive Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018 , 3, 337-347	3.4	10
290	A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 108-113	5.8	9
289	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018 , 20, 97-170	3.8	639
288	Structural brain changes in first episode mania with and without psychosis: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>World Journal of Biological Psychiatry</i> , 2018 , 19, S30-S40	3.8	10
287	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 330-348	3.8	20
286	Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2018 , 226, 294-300	6.6	5
285	Quality of life in bipolar disorder: towards a dynamic understanding. <i>Psychological Medicine</i> , 2018 , 48, 1111-1118	6.9	25
284	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. <i>Focus (American Psychiatric Publishing)</i> , 2018 , 16, 85-94	1.1	7
283	Use of Placebo in Clinical Trials of Psychotropic Medication. <i>Canadian Journal of Psychiatry</i> , 2018 , 63, 338-341	4.8	3
282	Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. <i>International Journal of Methods in Psychiatric Research</i> , 2018 , 27, e1736	4.3	14
281	The association of duration and severity of disease with executive function: Differences between drug-naïve patients with bipolar and unipolar depression. <i>Journal of Affective Disorders</i> , 2018 , 238, 412-417 ^{6.6}		9
280	Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	3
279	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. <i>Journal of Affective Disorders</i> , 2018 , 227, 542-549	6.6	46
278	Comparison of 21 Antidepressants. <i>Focus (American Psychiatric Publishing)</i> , 2018 , 16, 4s	1.1	
277	Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 2861-2877	3.1	23
276	Inclusion of mental health in global economic development. <i>BJPsych International</i> , 2018 , 15, 74-76	1.2	1

275	Revising , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018 , 52, 1173-1182	2.6	12
274	Non-linear Entropy Analysis in EEG to Predict Treatment Response to Repetitive Transcranial Magnetic Stimulation in Depression. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1188	5.6	13
273	Evidence for the Efficacy of Bright Light Therapy for Bipolar Depression. <i>American Journal of Psychiatry</i> , 2018 , 175, 905-906	11.9	9
272	Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. <i>Lancet Psychiatry</i> , 2017 , 4, 208-217	23.3	39
271	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. <i>Canadian Journal of Psychiatry</i> , 2017 , 62, 77-78	4.8	
270	Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. <i>Canadian Journal of Psychiatry</i> , 2017 , 62, 353-354	4.8	
269	The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 412-418	1.7	42
268	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. <i>Nature Communications</i> , 2017 , 8, 15497	17.4	93
267	Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2017 , 210, 403-407	5.4	38
266	Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder. <i>Translational Psychiatry</i> , 2017 , 7, e1071	8.6	11
265	APEC digital hub for mental health. <i>Lancet Psychiatry</i> , 2017 , 4, e3-e4	23.3	5
264	Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12-month study. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 135, 239-249	6.5	18
263	Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. <i>Lancet Psychiatry</i> , 2017 , 4, 839-849	23.3	249
262	A multicomponent intervention for the management of chronic pain in older adults: study protocol for a randomized controlled trial. <i>Trials</i> , 2017 , 18, 528	2.8	5
261	Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis. <i>Journal of Psychopharmacology</i> , 2017 , 31, 1204-1214	4.6	1
260	A sparse representation-based method for parcellation of the resting brain and its application to treatment-resistant major depressive disorder. <i>Journal of Neuroscience Methods</i> , 2017 , 290, 57-68	3	5
259	The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 343-349	2.2	6
258	Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression. <i>Scientific Reports</i> , 2017 , 7, 7473	4.9	15

257	Subcortical structural volumes in recently remitted first episode mania. <i>Journal of Affective Disorders</i> , 2017 , 222, 23-27	6.6	7
256	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017 , 222, 14-20	6.6	20
255	Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Affective Disorders</i> , 2017 , 208, 291-297	6.6	15
254	Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 1383-1394	4.6	53
253	A Longitudinal Study of the Relationships Between Mood Symptoms, Body Mass Index, and Serum Adipokines in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 441-448	4.6	10
252	Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 115-121	4.6	55
251	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 873-881	4.6	63
250	Impact of Cognitive Impairment on Functioning in Patients With Depression. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, e1430	4.6	
249	Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. <i>Molecular Psychiatry</i> , 2016 , 21, 1050-6	15.1	34
248	Selection of cognitive tests for trials of therapeutic agents. <i>Lancet Psychiatry</i> , 2016 , 3, 499	23.3	13
247	Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>Lancet Psychiatry</i> , 2016 , 3, 1138-1146	23.3	80
246	S-adenosyl methionine (SAME) for depression in adults. <i>The Cochrane Library</i> , 2016 , 10, CD011286	5.2	40
245	Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome. <i>Bipolar Disorders</i> , 2016 , 18, 511-519	3.8	51
244	The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2016 , 203, 55-61	6.6	22
243	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. <i>BMC Psychiatry</i> , 2016 , 16, 105	4.2	80
242	Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. <i>Psychoneuroendocrinology</i> , 2016 , 65, 76-83	5	25
241	Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder. <i>British Journal of Psychiatry</i> , 2016 , 208, 146-52	5.4	14
240	Sinus Tachycardia Induced by Methocarbamol and Repetitive Transcranial Magnetic Stimulation (rTMS). <i>Brain Stimulation</i> , 2016 , 9, 156-8	5.1	6

239	Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2016 , 73, 56-63	14.5	134
238	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. <i>Innovations in Clinical Neuroscience</i> , 2016 , 13, 20-31	1	8
237	Preferred Features of E-Mental Health Programs for Prevention of Major Depression in Male Workers: Results From a Canadian National Survey. <i>Journal of Medical Internet Research</i> , 2016 , 18, e132	7.6	17
236	The Effects of an E-Mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2016 , 5, e218	2	9
235	Midodrine for severe orthostatic hypotension. <i>Drug and Therapeutics Bulletin</i> , 2016 , 54, 54-6	0.9	4
234	Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management. <i>Focus (American Psychiatric Publishing)</i> , 2016 , 14, 194-206	1.1	19
233	The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>CNS Drugs</i> , 2016 , 30, 405-17	6.7	9
232	Heparin-Based Polyelectrolyte Complex Enhances the Therapeutic Efficacy of Bone Morphogenetic Protein-2 for Posterolateral Fusion in a Large Animal Model. <i>Spine</i> , 2016 , 41, 1199-1207	3.3	7
231	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and Methods. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 506-9	4.8	47
230	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 588-603	4.8	114
229	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 510-23	4.8	140
228	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 540-60	4.8	469
227	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 524-39	4.8	160
226	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 561-75	4.8	270
225	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 576-87	4.8	146
224	Enhanced inflammatory and T-helper-1 type responses but suppressed lymphocyte proliferation in patients with seasonal affective disorder and treated by light therapy. <i>Journal of Affective Disorders</i> , 2015 , 185, 90-6	6.6	19
223	Verbal memory impairment in new onset bipolar disorder: Relationship with frontal and medial temporal morphology. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 249-60	3.8	10
222	The relationship between burnout and depressive symptoms in patients with depressive disorders. <i>Journal of Affective Disorders</i> , 2015 , 172, 361-6	6.6	16

221	A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. <i>Psychological Medicine</i> , 2015 , 45, 693-704	6.9	236
220	A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability. <i>Journal of Psychiatric Research</i> , 2015 , 62, 23-30	5.2	78
219	Course and outcome following a first episode of mania: four-year prospective data from the Systematic Treatment Optimization Program (STOP-EM). <i>Journal of Affective Disorders</i> , 2015 , 175, 411-7	6.6	16
218	Recovery and recurrence following a first episode of mania: a systematic review and meta-analysis of prospectively characterized cohorts. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 1241-8	4.6	35
217	Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. <i>Annals of Clinical Psychiatry</i> , 2015 , 27, 142-9	1.4	32
216	12-month longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder. <i>Bipolar Disorders</i> , 2014 , 16, 159-71	3.8	47
215	Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i> , 2014 , 14 Suppl 1, S1	4.2	396
214	Early switching strategies in antidepressant non-responders: current evidence and future research directions. <i>CNS Drugs</i> , 2014 , 28, 601-9	6.7	46
213	Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder. <i>Value in Health</i> , 2014 , 17, 183-95	3.3	9
212	Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014 , 166, 307-14	6.6	12
211	Body mass index-related regional gray and white matter volume reductions in first-episode mania patients. <i>Biological Psychiatry</i> , 2014 , 76, 138-45	7.9	38
210	Research-track programs for residents in psychiatry: a review of literature and a report of 3 Canadian experiences. <i>Canadian Journal of Psychiatry</i> , 2014 , 59, 268-75	4.8	7
209	Neurocognitive functioning in overweight and obese patients with bipolar disorder: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Canadian Journal of Psychiatry</i> , 2014 , 59, 639-48	4.8	17
208	Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. <i>Canadian Journal of Psychiatry</i> , 2014 , 59, 649-54	4.8	189
207	S-adenosyl methionine (SAM-e) for depression in adults 2014 ,		2
206	Long-term neuropsychological safety of subgenual cingulate gyrus deep brain stimulation for treatment-resistant depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2014 , 26, 126-33	2.7	18
205	Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. <i>International Clinical Psychopharmacology</i> , 2014 , 29, 239-51	2.2	21
204	Childhood maltreatment and corpus callosum volume in recently diagnosed patients with bipolar I disorder: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Psychiatric Research</i> , 2014 , 48, 65-72	5.2	16

203	Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, e587-93	4.6	37
202	The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, 1359-70	4.6	128
201	Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder. <i>Sleep Medicine</i> , 2013 , 14, 943-9	4.6	28
200	The impact of childhood trauma on cognitive functioning in patients recently recovered from a first manic episode: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Affective Disorders</i> , 2013 , 148, 424-30	6.6	24
199	Relationship between frontostriatal morphology and executive function deficits in bipolar I disorder following a first manic episode: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Bipolar Disorders</i> , 2013 , 15, 657-68	3.8	19
198	Do the symptoms of bipolar disorder really show seasonal variation?. <i>Bipolar Disorders</i> , 2013 , 15, 808-10	3.8	2
197	Preclinical evaluation of strontium-containing bioactive bone cement. <i>Materials Science and Engineering C</i> , 2013 , 33, 5100-4	8.3	4
196	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated bipolar disorder guidelines. <i>Bipolar Disorders</i> , 2013 , 15, 338-9	3.8	1
195	A double-blind, placebo-controlled study of adjunctive calcitonin nasal spray in acute refractory mania. <i>Bipolar Disorders</i> , 2013 , 15, 359-64	3.8	5
194	The relationship between clinical outcomes and quality of life in first-episode mania: a longitudinal analysis. <i>Bipolar Disorders</i> , 2013 , 15, 188-98	3.8	24
193	Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials. <i>Journal of Affective Disorders</i> , 2013 , 150, 408-14	6.6	38
192	Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. <i>British Journal of Psychiatry</i> , 2013 , 203, 358-65	5.4	33
191	Antidepressants and QTc prolongation. <i>Journal of Psychiatry and Neuroscience</i> , 2013 , 38, E5-6	4.5	18
190	Escitalopram and QTc prolongation. <i>Journal of Psychiatry and Neuroscience</i> , 2013 , 38, E11	4.5	15
189	Conceptualising the neurobiology of fatigue. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013 , 47, 312-6	2.6	14
188	Fatigue and occupational functioning in major depressive disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013 , 47, 989-91	2.6	13
187	Systematic review of neurocognition and occupational functioning in major depressive disorder. <i>Neuropsychiatry</i> , 2013 , 3, 97-105	1.8	29
186	Author response. <i>Journal of Psychiatry and Neuroscience</i> , 2013 , 38, E11-2	4.5	

185	Rapid screening for perceived cognitive impairment in major depressive disorder. <i>Annals of Clinical Psychiatry</i> , 2013 , 25, 135-40	1.4	18
184	Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. <i>Bipolar Disorders</i> , 2012 , 14, 478-87	3.8	151
183	Onset, time course and trajectories of improvement with antidepressants. <i>European Neuropsychopharmacology</i> , 2012 , 22 Suppl 3, S492-8	1.2	52
182	Direct health care costs of treating seasonal affective disorder: a comparison of light therapy and fluoxetine. <i>Depression Research and Treatment</i> , 2012 , 2012, 628434	3.8	7
181	Seasonal affective disorders. <i>Issues in Mental Health Nursing</i> , 2012 , 33, 266-8	1.5	1
180	Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder. <i>International Clinical Psychopharmacology</i> , 2012 , 27, 91-9	2.2	18
179	A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. <i>Journal of Neurosurgery</i> , 2012 , 116, 315-22	3.2	277
178	Deep brain stimulation interruption and suicidality. <i>Journal of Neurosurgery</i> , 2012 , 116, 467-8	3.2	3
177	Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning?. <i>Depression Research and Treatment</i> , 2012 , 2012, 630206	3.8	40
176	Selective-serotonin reuptake inhibitors 2012 , 12-25		
175	The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5976-89	3.3	48
174	The prevalence and impact of depression in self-referred clients attending an employee assistance program. <i>Journal of Occupational and Environmental Medicine</i> , 2012 , 54, 1395-9	2	3
173	Positron emission tomography study of the effects of tryptophan depletion on brain serotonin(2) receptors in subjects recently remitted from major depression. <i>Archives of General Psychiatry</i> , 2012 , 69, 601-9		14
172	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. <i>Annals of Clinical Psychiatry</i> , 2012 , 24, 23-37	1.4	67
171	The association of elevated body mass index with reduced brain volumes in first-episode mania. <i>Biological Psychiatry</i> , 2011 , 70, 381-7	7.9	52
170	Comparative efficacy of escitalopram in the treatment of major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 39-49	3.1	23
169	Do symptoms of bipolar disorder exhibit seasonal variation? A multisite prospective investigation. <i>Bipolar Disorders</i> , 2011 , 13, 687-95	3.8	22
168	Evaluation of a disease-management intervention designed to reduce depression disability. <i>Journal of Evaluation in Clinical Practice</i> , 2011 , 17, 322-5	2.5	1

167	Clinical effectiveness: the importance of psychosocial functioning outcomes. <i>Journal of Affective Disorders</i> , 2011 , 132 Suppl 1, S9-S13	6.6	64
166	Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. <i>Psychological Medicine</i> , 2011 , 41, 971-82	6.9	63
165	Telephone-administered cognitive-behavioral therapy for clients with depressive symptoms in an employee assistance program: a pilot study. <i>Annals of Clinical Psychiatry</i> , 2011 , 23, 11-6	1.4	5
164	The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Bipolar Disorders</i> , 2010 , 12, 616-26	3.8	27
163	The importance of early symptom relief in antidepressant treatment: focus on agomelatine. <i>Journal of Psychopharmacology</i> , 2010 , 24, 27-30	4.6	14
162	A season-of-birth/DRD4 interaction predicts maximal body mass index in women with bulimia nervosa. <i>Neuropsychopharmacology</i> , 2010 , 35, 1729-33	8.7	27
161	Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. <i>British Journal of Psychiatry</i> , 2010 , 196, 474-9	5.4	61
160	Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 199-203	2.2	18
159	Brain serotonin-2 receptors in acute mania. <i>British Journal of Psychiatry</i> , 2010 , 196, 47-51	5.4	16
158	Neurocognitive functioning in patients with bipolar I disorder recently recovered from a first manic episode. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1234-42	4.6	115
157	Relief of chronic or resistant depression (Re-ChORD): a pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression. <i>Journal of Affective Disorders</i> , 2010 , 123, 243-8	6.6	16
156	Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Affective Disorders</i> , 2010 , 124, 108-17	6.6	24
155	Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2010 , 124, 228-34	6.6	92
154	Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. <i>Depression and Anxiety</i> , 2010 , 27, 964-76	8.4	59
153	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. <i>Journal of Affective Disorders</i> , 2009 , 117 Suppl 1, S44-53	6.6	140
152	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. <i>Journal of Affective Disorders</i> , 2009 , 117 Suppl 1, S54-64	6.6	75
151	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. <i>Journal of Affective Disorders</i> , 2009 , 117 Suppl 1, S26-43	6.6	298
150	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. <i>Journal of Affective Disorders</i> , 2009 , 117 Suppl 1, S15-25	6.6	125

149	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. <i>Journal of Affective Disorders</i> , 2009 , 117 Suppl 1, S1-2	6.6	114
148	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. <i>Journal of Affective Disorders</i> , 2009 , 117 Suppl 1, S5-14	6.6	105
147	A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. <i>BMC Psychiatry</i> , 2009 , 9, 78	4.2	43
146	Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project. <i>Comprehensive Psychiatry</i> , 2009 , 50, 1-8	7.3	46
145	Evidence of a biological effect of light therapy on the retina of patients with seasonal affective disorder. <i>Biological Psychiatry</i> , 2009 , 66, 253-8	7.9	71
144	Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 447-58	5.8	292
143	Course and outcome after the first manic episode in patients with bipolar disorder: prospective 12-month data from the Systematic Treatment Optimization Program For Early Mania project. <i>Canadian Journal of Psychiatry</i> , 2009 , 54, 105-12	4.8	76
142	Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 137-9	5.8	41
141	Addressing circadian rhythm disturbances in depressed patients. <i>Journal of Psychopharmacology</i> , 2008 , 22, 13-8	4.6	14
140	Burden of bipolar depression: impact of disorder and medications on quality of life. <i>CNS Drugs</i> , 2008 , 22, 389-406	6.7	58
139	Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. <i>Canadian Journal of Psychiatry</i> , 2008 , 53, 621-31	4.8	179
138	Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. <i>International Clinical Psychopharmacology</i> , 2008 , 23, 181-7	2.2	19
137	Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1589-601	4.6	94
136	Psychosocial outcomes following electroconvulsive therapy in a community setting: retrospective chart review with 2-year follow-up. <i>Canadian Journal of Psychiatry</i> , 2007 , 52, 598-604	4.8	4
135	A controlled trial of the Litebook light-emitting diode (LED) light therapy device for treatment of Seasonal Affective Disorder (SAD). <i>BMC Psychiatry</i> , 2007 , 7, 38	4.2	46
134	A magnetic resonance imaging study of mood stabilizer- and neuroleptic-naïve first-episode mania. <i>Bipolar Disorders</i> , 2007 , 9, 693-7	3.8	51
133	The impact of bipolar disorder upon work functioning: a qualitative analysis. <i>Bipolar Disorders</i> , 2007 , 9, 126-43	3.8	89
132	Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007 , 7, 559-76	2.2	2

131	Seasonal affective disorder: a clinical update. <i>Annals of Clinical Psychiatry</i> , 2007 , 19, 239-46	1.4	84
130	Which antidepressants have demonstrated superior efficacy? A review of the evidence. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 323-9	2.2	103
129	Quality of Life in Bipolar Disorder: A Review of the Literature. <i>Focus (American Psychiatric Publishing)</i> , 2007 , 5, 117-134	1.1	5
128	High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2007 , 22 Suppl 2, S21-5	2.2	25
127	Quality of life as an outcome indicator in patients with seasonal affective disorder: results from the Can-SAD study. <i>Psychological Medicine</i> , 2007 , 37, 727-36	6.9	21
126	A pilot study of adherence with light treatment for seasonal affective disorder. <i>Psychiatry Research</i> , 2007 , 149, 315-20	9.9	22
125	Long-term and preventative treatment for seasonal affective disorder. <i>CNS Drugs</i> , 2007 , 21, 901-9	6.7	39
124	Quality of life impairment in bipolar disorder 2007 , 253-274		5
123	O sweet spot where art thou? Light treatment of Seasonal Affective Disorder and the circadian time of sleep. <i>Journal of Affective Disorders</i> , 2006 , 90, 227-31	6.6	20
122	Personality and seasonal affective disorder: results from the CAN-SAD study. <i>Journal of Affective Disorders</i> , 2006 , 93, 35-42	6.6	18
121	The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. <i>Pharmacopsychiatry</i> , 2006 , 39, 180-4	2	64
120	A birth-season/DRD4 gene interaction predicts weight gain and obesity in women with seasonal affective disorder: A seasonal thrifty phenotype hypothesis. <i>Neuropsychopharmacology</i> , 2006 , 31, 2498-503	8.7	68
119	The Relevance of an Employee Assistance Program to the Treatment of Workplace Depression. <i>Journal of Workplace Behavioral Health</i> , 2006 , 21, 67-77	0.6	9
118	Challenges in the treatment of anxiety disorders: beyond guidelines. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006 , 10 Suppl 3, 18-24	2.4	1
117	Generalized anxiety disorder: how to treat, and for how long?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006 , 10 Suppl 1, 10-5	2.4	2
116	Oxcarbazepine in the treatment of bipolar disorder: a review. <i>Canadian Journal of Psychiatry</i> , 2006 , 51, 540-5	4.8	22
115	The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. <i>American Journal of Psychiatry</i> , 2006 , 163, 805-12	11.9	162
114	Sleep disturbances and depression: a challenge for antidepressants. <i>International Clinical Psychopharmacology</i> , 2006 , 21 Suppl 1, S25-9	2.2	95

113	Bipolar disorder and quality of life: a patient-centered perspective. <i>Quality of Life Research</i> , 2006 , 15, 25-37	3.7	164
112	Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. <i>Journal of Psychiatry and Neuroscience</i> , 2006 , 31, 122-31	4.5	110
111	Therapeutic mechanism in seasonal affective disorder: do fluoxetine and light operate through advancing circadian phase?. <i>Chronobiology International</i> , 2005 , 22, 937-43	3.6	36
110	Quality of life in bipolar disorder: a review of the literature. <i>Health and Quality of Life Outcomes</i> , 2005 , 3, 72	3	153
109	Perceived quality of life in patients with bipolar disorder. Does group psychoeducation have an impact?. <i>Canadian Journal of Psychiatry</i> , 2005 , 50, 95-100	4.8	53
108	Update on the biology of seasonal affective disorder. <i>CNS Spectrums</i> , 2005 , 10, 635-46; quiz 1-14	1.8	73
107	A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania. <i>Bipolar Disorders</i> , 2005 , 7 Suppl 5, 53-7	3.8	28
106	Oxcarbazepine add-on in the treatment of refractory bipolar disorder. <i>Bipolar Disorders</i> , 2005 , 7 Suppl 5, 37-42	3.8	14
105	Using metaanalysis to evaluate evidence: practical tips and traps. <i>Canadian Journal of Psychiatry</i> , 2005 , 50, 167-74	4.8	39
104	Quality of life in patients with seasonal affective disorder: summer vs winter scores. <i>Canadian Journal of Psychiatry</i> , 2005 , 50, 292-5	4.8	13
103	A comparison of personality function among patients with seasonal depression, nonseasonal depression, and nonclinical participants. <i>Journal of Personality Disorders</i> , 2004 , 18, 448-58	2.6	2
102	Priorities in treating depression only. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004 , 8 Suppl 1, 25-9	2.4	8
101	Brightening depression. <i>Science</i> , 2004 , 303, 467-9	33.3	58
100	Treatment of seasonal affective disorder: unipolar versus bipolar differences. <i>Current Psychiatry Reports</i> , 2004 , 6, 478-85	9.1	16
99	Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis. <i>BMC Family Practice</i> , 2004 , 5, 19	2.6	21
98	The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. <i>Biological Psychiatry</i> , 2004 , 56, 665-9	7.9	84
97	Generic and health-related quality of life in patients with seasonal and nonseasonal depression. <i>Psychiatry Research</i> , 2004 , 128, 245-51	9.9	24
96	Electroretinography in patients with winter seasonal affective disorder. <i>Psychiatry Research</i> , 2004 , 127, 27-34	9.9	56

95	Does neuroimmune dysfunction mediate seasonal mood changes in winter depression?. <i>Medical Hypotheses</i> , 2004 , 63, 567-73	3.8	13
94	Childhood inattention and dysphoria and adult obesity associated with the dopamine D4 receptor gene in overeating women with seasonal affective disorder. <i>Neuropsychopharmacology</i> , 2004 , 29, 179-86	8.7	79
93	Hard times and good friends: negative life events and social support in patients with seasonal and nonseasonal depression. <i>Canadian Journal of Psychiatry</i> , 2004 , 49, 408-11	4.8	6
92	Citalopram and Bupropion-SR. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 337-340	4.6	61
91	Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 337-40	4.6	19
90	Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. <i>Canadian Journal of Psychiatry</i> , 2004 , 49, 175-265	4.8	19
89	The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. <i>Psychological Medicine</i> , 2003 , 33, 785-92	6.9	33
88	The interpersonal expression of perfection: perfectionistic self-presentation and psychological distress. <i>Journal of Personality and Social Psychology</i> , 2003 , 84, 1303-25	6.5	261
87	Acute tryptophan depletion induces depressive symptoms in subgroups of recovered depressed patients. <i>Psychological Medicine</i> , 2003 , 33, 1133-4; author reply 1134-5	6.9	1
86	Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. <i>Bipolar Disorders</i> , 2003 , 5 Suppl 2, 36-47	3.8	85
85	Advances in treatment of mood and anxiety disorders: focus on atypical antipsychotics. <i>Bipolar Disorders</i> , 2003 , 5 Suppl 2, 5-6	3.8	1
84	Review: antidepressants and psychotherapy may be equally effective for promoting remission in major depressive disorder. <i>Evidence-Based Mental Health</i> , 2003 , 6, 45	11.1	2
83	Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 65-86	5.9	19
82	Evidence supports validity of seasonal affective disorder. <i>Canadian Journal of Psychiatry</i> , 2002 , 47, 786; author reply 786-7	4.8	2
81	Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. <i>Journal of Affective Disorders</i> , 2002 , 71, 229-33	6.6	65
80	A comparison of open treatment of seasonal major and minor depression with light therapy. <i>Journal of Affective Disorders</i> , 2002 , 71, 243-8	6.6	24
79	PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. <i>American Journal of Psychiatry</i> , 2002 , 159, 768-74	11.9	105
78	Breaking the myths: new treatment approaches for chronic depression. <i>Canadian Journal of Psychiatry</i> , 2002 , 47, 635-43	4.8	24

77	PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. <i>American Journal of Psychiatry</i> , 2002 , 159, 1718-23	11.9	73
76	Seasonal affective disorder: the latitude hypothesis revisited. <i>Canadian Journal of Psychiatry</i> , 2002 , 47, 787-8	4.8	8
75	Bipolar spectrum disorders. New perspectives. <i>Canadian Family Physician</i> , 2002 , 48, 896-904	0.9	19
74	Combining antidepressants for treatment-resistant depression: a review. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 685-93	4.6	86
73	Immune-inflammatory markers in patients with seasonal affective disorder: effects of light therapy. <i>Journal of Affective Disorders</i> , 2001 , 63, 27-34	6.6	39
72	Seasonal depression: the dual vulnerability hypothesis revisited. <i>Journal of Affective Disorders</i> , 2001 , 63, 123-32	6.6	63
71	Effects of alpha-methyl-para-tyrosine-induced catecholamine depletion in patients with seasonal affective disorder in summer remission. <i>Neuropsychopharmacology</i> , 2001 , 25, S97-101	8.7	29
70	Patients' preferences and counselling for depression in primary care. <i>Lancet, The</i> , 2001 , 357, 575-6	4.0	4
69	Effects of rapid tryptophan depletion on brain 5-HT(2) receptors: a PET study. <i>British Journal of Psychiatry</i> , 2001 , 178, 448-53	5.4	73
68	An open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 164-8	4.6	15
67	Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 975-80	4.6	38
66	Brain serotonin ₂ receptors in major depression: a positron emission tomography study. <i>Archives of General Psychiatry</i> , 2000 , 57, 850-8		141
65	Effects of rapid tryptophan depletion in patients with seasonal affective disorder in natural summer remission. <i>Psychological Medicine</i> , 2000 , 30, 79-87	6.9	36
64	A PET study of brain 5-HT ₂ receptors and their correlation with platelet 5-HT ₂ receptors in healthy humans. <i>Psychopharmacology</i> , 2000 , 151, 424-7	4.7	9
63	Effects of light therapy on suicidal ideation in patients with winter depression. <i>Journal of Clinical Psychiatry</i> , 2000 , 61, 30-2	4.6	28
62	Does the addition of pindolol accelerate the response to electroconvulsive therapy in patients with major depression? A double-blind, placebo-controlled pilot study. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 373-8	1.7	12
61	Growth hormone response to baclofen in patients with mania: a pilot study. <i>Psychopharmacology</i> , 1999 , 147, 280-4	4.7	17
60	Hypothermic, ACTH, and cortisol responses to ipsapirone in patients with mania and healthy controls. <i>Journal of Affective Disorders</i> , 1999 , 54, 295-301	6.6	18

59	Growth hormone response to baclofen in patients with seasonal affective disorder: effects of light therapy. <i>Psychoneuroendocrinology</i> , 1999 , 24, 143-53	5	2
58	A controlled study of light therapy in women with late luteal phase dysphoric disorder. <i>Psychiatry Research</i> , 1999 , 86, 185-92	9.9	73
57	Clinical predictors of short-term outcome in electroconvulsive therapy. <i>Canadian Journal of Psychiatry</i> , 1999 , 44, 158-63	4.8	9
56	Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. <i>Archives of General Psychiatry</i> , 1999 , 56, 705-11		131
55	Adverse effects of pindolol augmentation in patients with bipolar depression. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 383-4	1.7	6
54	Effects of lamotrigine on the 5-HT _{1A} receptor function in healthy human males. <i>Journal of Affective Disorders</i> , 1998 , 49, 157-62	6.6	16
53	Divalproex sodium attenuates growth hormone response to baclofen in healthy human males. <i>Neuropsychopharmacology</i> , 1998 , 18, 370-6	8.7	8
52	Seasonal mood change and personality: an investigation of genetic co-morbidity. <i>Psychiatry Research</i> , 1998 , 78, 1-7	9.9	11
51	Cortisol, hypothermic, and behavioral responses to ipsapirone in patients with bipolar depression and normal controls. <i>Neuropsychobiology</i> , 1998 , 38, 6-12	4	25
50	A community-based clinic survey of antidepressant use in persons with schizophrenia. <i>Canadian Journal of Psychiatry</i> , 1998 , 43, 513-6	4.8	6
49	A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 268-73	1.7	19
48	Seasonality of symptoms in women with late luteal phase dysphoric disorder. <i>American Journal of Psychiatry</i> , 1997 , 154, 1436-41	11.9	35
47	L-tryptophan augmentation of light therapy in patients with seasonal affective disorder. <i>Canadian Journal of Psychiatry</i> , 1997 , 42, 303-6	4.8	24
46	Light therapy for depressive disorders: indications and efficacy. <i>Modern Problems of Pharmacopsychiatry</i> , 1997 , 25, 215-34		15
45	Mania, Depression, and Mood Dependent Memory. <i>Cognition and Emotion</i> , 1997 , 11, 607-618	2.3	38
44	Effects of chronic lithium treatment on retinal electrophysiologic function. <i>Biological Psychiatry</i> , 1997 , 41, 737-42	7.9	8
43	Growth hormone response to sumatriptan (5-HT _{1D} agonist) challenge in seasonal affective disorder: effects of light therapy. <i>Biological Psychiatry</i> , 1997 , 42, 24-9	7.9	44
42	Gender differences in the heritability of seasonal mood change. <i>Psychiatry Research</i> , 1997 , 70, 145-54	9.9	59

41	Sumatriptan-induced growth hormone release in patients with major depression, mania, and normal controls. <i>Neuropsychopharmacology</i> , 1997 , 17, 258-63	8.7	16
40	Effects of divalproex sodium on 5-HT _{1A} receptor function in healthy human males: hypothermic, hormonal, and behavioral responses to ipsapirone. <i>Neuropsychopharmacology</i> , 1997 , 17, 382-90	8.7	16
39	The relationship between seasonal mood change and personality: more apparent than real?. <i>Acta Psychiatrica Scandinavica</i> , 1997 , 95, 539-43	6.5	26
38	Atypical depressive symptoms in seasonal and non-seasonal mood disorders. <i>Journal of Affective Disorders</i> , 1997 , 44, 39-44	6.6	41
37	Role of serotonin ₃ receptors in prolactin release induced by electroconvulsive therapy: a study with ondansetron. <i>Psychiatry Research</i> , 1996 , 60, 33-9	9.9	1
36	The validity of atypical depression in DSM-IV. <i>Comprehensive Psychiatry</i> , 1996 , 37, 375-83	7.3	35
35	Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. <i>Archives of General Psychiatry</i> , 1996 , 53, 41-4		133
34	Effect of stimulus intensity on prolactin and cortisol release induced by unilateral electroconvulsive therapy. <i>Neuropsychopharmacology</i> , 1996 , 15, 263-70	8.7	17
33	Atypical depressive symptoms and clusters in unipolar and bipolar depression. <i>Acta Psychiatrica Scandinavica</i> , 1996 , 94, 421-7	6.5	57
32	Major depression, minor depression, and double depression: are they distinct clinical entities?. <i>American Journal of Medical Genetics Part A</i> , 1996 , 67, 347-53		31
31	Seasonality of symptoms in anorexia and bulimia nervosa. <i>International Journal of Eating Disorders</i> , 1996 , 19, 35-44	6.3	22
30	Prolactin response to buspirone challenge in the presence of dopaminergic blockade. <i>Biological Psychiatry</i> , 1995 , 38, 235-9	7.9	27
29	Treatment of seasonal affective disorder: a review. <i>Canadian Journal of Psychiatry</i> , 1995 , 40, 457-66	4.8	43
28	Mood Disorder Service Genetic Database: morbidity risks for mood disorders in 3,942 first-degree relatives of 671 index cases with single depression, recurrent depression, bipolar I, or bipolar II. <i>American Journal of Medical Genetics Part A</i> , 1994 , 54, 132-40		46
27	Morning light therapy for winter depression: predictors of response. <i>Acta Psychiatrica Scandinavica</i> , 1994 , 89, 97-101	6.5	40
26	Research funding of psychiatric disorders in Canada: a snapshot, 1990-1991. <i>Canadian Journal of Psychiatry</i> , 1994 , 39, 141-6	4.8	4
25	Seasonal affective disorders. <i>Current Opinion in Psychiatry</i> , 1994 , 7, 9-13	4.9	5
24	Eating attitudes in seasonal affective disorder and bulimia nervosa. <i>Journal of Affective Disorders</i> , 1993 , 29, 219-25	6.6	26

23	Comparison of fluoxetine and desipramine in depressed outpatients. <i>Current Therapeutic Research</i> , 1993 , 53, 457-465	2.4	11
22	Light visor treatment for seasonal affective disorder: a multicenter study. <i>Psychiatry Research</i> , 1993 , 46, 29-39	9.9	62
21	Chronic schizophrenia and idiopathic Parkinson's disease. <i>Canadian Journal of Psychiatry</i> , 1993 , 38, 75-7	4.8	20
20	Obtaining a family psychiatric history: is it worth the effort?. <i>Canadian Journal of Psychiatry</i> , 1993 , 38, 590-4	4.8	3
19	Effect of Stimulus Energy on Electroconvulsive Therapy-Induced Prolactin Release. <i>Convulsive Therapy</i> , 1993 , 9, 23-27		3
18	The effects of ultraviolet-A wavelengths in light therapy for seasonal depression. <i>Journal of Affective Disorders</i> , 1992 , 24, 237-43	6.6	31
17	Hypersomnia and morning light therapy for winter depression. <i>Biological Psychiatry</i> , 1992 , 31, 1062-4	7.9	10
16	Electroretinography in seasonal affective disorder. <i>Psychiatry Research</i> , 1992 , 43, 55-63	9.9	44
15	ECT-induced prolactin release: Effect of sex, electrode placement and serotonin uptake inhibition. <i>Human Psychopharmacology</i> , 1991 , 6, 155-160	2.3	5
14	Seasonal mood symptoms in bulimia nervosa and seasonal affective disorder. <i>Comprehensive Psychiatry</i> , 1991 , 32, 552-8	7.3	33
13	Seasonal affective disorder presenting as chronic fatigue syndrome. <i>Canadian Journal of Psychiatry</i> , 1991 , 36, 680-2	4.8	2
12	A psychiatric fellowship in the United States. <i>Canadian Journal of Psychiatry</i> , 1990 , 35, 243-7	4.8	4
11	Melatonin suppression in bipolar and unipolar mood disorders. <i>Psychiatry Research</i> , 1990 , 33, 129-34	9.9	76
10	Phototherapy for depressive disorders: a review. <i>Canadian Journal of Psychiatry</i> , 1989 , 34, 140-7	4.8	43
9	Light therapy for seasonal bulimia. <i>American Journal of Psychiatry</i> , 1989 , 146, 1640-1	11.9	8
8	The clinical use of EEG in a general psychiatric setting. <i>Psychiatric Services</i> , 1988 , 39, 533-6	3.3	2
7	ECT in the treatment of mixed depression and dementia. <i>British Journal of Psychiatry</i> , 1988 , 152, 281-4	5.4	24
6	The lateralization of atypical facial pain. <i>Canadian Journal of Psychiatry</i> , 1988 , 33, 100-2	4.8	6

5	Antidepressant Drug Studies in the Elderly. <i>Psychiatric Clinics of North America</i> , 1988 , 11, 215-233	3.1	30
4	Subjective measures of cognitive dysfunction in major depressive disorder 242-256		1
3	Assessment Scales in Depression and Anxiety - CORPORATE		5
2	Visual QC Protocol for FreeSurfer Cortical Parcellations from Anatomical MRI		1
1	Baseline functional connectivity in resting state networks associated with depression and remission status after 16 weeks of pharmacotherapy: A CAN-BIND Report		1